We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
Caitlin Costello, MD
Sagar Lonial, MD, FACP
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
Integrating Bispecific Antibodies Into Clinical Practice
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Clinical Challenges With Triple-Class or Penta-Refractory MM
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Efficacy Data for Bispecific Antibodies in RRMM
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma
Considerations for Dosing Bispecific Antibodies
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Implementation of the 2022 AHA/ASA Guideline for the Management of Patients with Spontaneous Intracerebral Hemorrhage—Are You Doing Enough?
W. Brian Gibler, MD, FACEP, FACC, FAHA
Rhonda Cadena, MD, FNCS, FCCM
Adrian R. Parry-Jones, FRCP, PhD
Stuart Connolly, MD, FRCPC
Providing Optimal Care for the Anticoagulated Patient with Intracranial Hemorrhage in the Acute Care Setting: Does the Patient Need Reversal, Repletion, or Surgery?
Natalie Kreitzer, MD, MS
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education